《国际肝病》：作为大会主席，请您介绍一下本届大会的规模及其亮点内容？

　　Galle教授：本届ILCA年会是一场具有突破性的会议。大会参会人数创下有史以来的最高纪录（960位），并且涵盖了所有的学科。谈到大会的亮点内容，nivolumab在肝癌免疫治疗方面的研究非常令人振奋， 免疫治疗也是目前研究的热点话题。在本届大会上，我们专门设立了一个关于肿瘤免疫及免疫治疗的专题会议。我期望未来随着生物学标志物的不断涌现，我们在肝癌免疫治疗方面有更大的作为。

　　It has been a record-breaking Congress. We have a large number of attendees (960) and we are covering the entire spectrum of disciplines. As far as highlights， the data on immuno-oncology was promising with nivolumab and hepatocellular carcinoma.Immunotherapy in general is an interesting topic. We had a workshop on immunopathogenesis and immunotherapy in HCC and I expect progress in this aspect as we get more and more trials that are biomarker driven.

　　《国际肝病》：近年来经导管肝动脉化疗栓塞（TACE）在肝癌治疗方面取得了不小进步，请您进行一下总结。

　　Galle教授：TACE治疗近年来越来越精准。由于患者的分层，TACE的临床数据有了很大的提高。我们正在研究如何筛选出适合TACE治疗的患者，哪些为不适合TACE治疗的患者，从而更好地为患者选择治疗方案，延长患者的总体生存。

　　TACE treatment has been getting more and more refined over the years. The data have been improved mainly because of patient selection probably. We are learning how to better separate patients who would benefit from those who will not benefit. This is something that results in better overall survival rates.

　　《国际肝病》：肝癌治疗的主要困难是如何对患者分层。目前，在寻找可帮助确立患者亚型的分子学标志物上我们有何进展？

　　Galle教授：目前，我们仍处于研究的早期阶段，然而也找到了一些可帮助确立患者亚型的分子学标志物，例如c-Met。有关Ras基因突变的研究正在进行，另一项利用高甲胎蛋白水平对患者进行分层的研究也已经开始。但是，与其他肿瘤，例如肺癌，所不同的是，我们在寻找分子学标志物的路上还需要更多的研究。

　　It is still early days. We have some markers such as c-Met. There is a study looking at RAS mutations. Another study is separating patients with high alpha-fetoprotein. But we are not at the point that now exists with lung cancer， for instance， and we need much more information on predictive markers.

　　《国际肝病》：ILCA专家指南共识是否计划在年底更新？

　　Galle教授：是的，我们计划将于今年年底提交指南的初稿，预计于明年颁布。

　　Yes. We will try to have the ILCA consensus guidelines updated and submit a manuscript by the end of the year， with the aim to publish them in 2016.

　　《国际肝病》：中国是肝癌大国，您对于我们在临床治疗和研究上有何评价和良好的建议？

　　Galle教授：中国的肝癌患者很多，而且患者的肿瘤大小较大。中国平均每年有3000例肝癌患者进行肝切除术。这也意味着中国在肝癌研究领域存在着巨大的机遇。我非常有信心，中国在大批科研工作者的努力下，通过大量的临床病例最终将取得从TACE治疗到化疗等各方面的巨大进步。

　　China has very high patient numbers and high-volume centers performing 3000 resections annually. There is a lot of opportunity for China and I am very optimistic about development across all fields from TACE to systemic therapy because of the large numbers of patients and many dedicated scientists.